Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,intangibleAssets,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,goodWill,treasuryStock,otherAssets,cash,totalCurrentLiabilities,shortLongTermDebt,otherStockholderEquity,propertyPlantEquipment,totalCurrentAssets,netReceivables,longTermDebt,inventory,accountsPayable,changeToLiabilities,netBorrowings,totalCashFromFinancingActivities,changeToOperatingActivities,issuanceOfStock,changeInCash,totalCashFromOperatingActivities,depreciation,changeToInventory,changeToAccountReceivables,otherCashflowsFromFinancingActivities,changeToNetincome,effectOfExchangeRate,WC,language,region,quoteType,triggerable,quoteSourceName,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,dividendDate,earningsTimestamp,earningsTimestampStart,earningsTimestampEnd,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,marketCap,priceHint,regularMarketChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,gmtOffSetMilliseconds,regularMarketDayRange,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,currency,esgPopulated,tradeable,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,exchange,shortName,exchangeDataDelayedBy,market,marketState,epsTrailingTwelveMonths,twoHundredDayAverageChangePercent,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Oct 14, 2010) 4","Short Ratio (Oct 14, 2010) 4","Short % of Float (Oct 14, 2010) 4","Short % of Shares Outstanding (Oct 14, 2010) 4","Shares Short (prior month Sep 14, 2010) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,industry,address2
t0,GNBT,-99495712,118446000,1202835,,8485334,12249968,9222550,5115320,-45300,-6363455,-6363455,,-1051624,,,,0,20695,6384150,65995,14848789,,8485334,9222550,8672951,422298124,90006629,-56333419,8502122,45923178,116277,509381,-479501629,25278241,34489342,753809,18821,1675027,64074335,8563199,753809,273238,2468826,52303,551573,232115,40961397,6030815.0,-187337.0,502303.0,123248.0,519264.0,1078995.0,576692.0,280407.0,385766.0,117188.0,170376.0,-14897252.0,,-61605509,en-US,US,EQUITY,False,Delayed Quote,244057,0.027199998,0.16484846,0.165 - 0.75,-0.5578,-0.74373335,0.165,0.75,1489449600,1560956340,1592405940,1592841600,-0.484,0.21625714,-0.024057135,-0.111243196,0.27455798,-0.08235797,22765322,4,-10.542234,-0.39710745,15,America/New_York,EDT,-14400000,0.19 - 0.209685,0.21485,0.0,0.0,0,0,finmb_404446,Other OTC,Generex Biotechnology Corporation,USD,233620,USD,False,False,0.1922,1630525703,-0.022649989,0.2,0.209685,0.19,286879,PNK,GENEREX BIOTECHNOLOGY CORP,0,us_market,PREPRE,-0.376,-0.29996568,,,,0.75,0.165,0.2163,0.2746,233.62k,244.06k,118.45M,,105.16M,2.42%,0.00%,211.98k,1.73,2.72%,2.66%,101.16k,,,,,,0.00%,"Mar 13, 2017",,7:5,"Feb 24, 2020","Jul 30, 2020","Apr 29, 2021",0.00%,"-4,952.49%",-43.84%,,692.76k,0.01,-95.90%,2.08M,-33.3M,-37.26M,-0.3760,,1.68M,0.01,10.6M,,0.04,-0.48,-2.35M,7.83M,Value,33025,Healthcare,15,"Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.",Miramar,416 364 2551,FL,1609372800,United States,http://generex.com/index.html,86400,10102 USA Today Way,Biotechnology,Suite 200
t-1,GNBT,-111491973,118446000,1558299,,-24406621,12987184,-24080582,6913295,-104984,-8576578,-8576578,,-587489,,,,0,0,8576578,104984,-15830043,,-24406621,-24080582,8902841,420021103,100622557,-68099790,4502122,45509951,112572,389188,-488724179,40321972,34489342,490714,21421,596032,59685413,10057281,490714,323755,1772592,169491,499473,617881,39317453,8838415.0,-67459.0,740447.0,-1852419.0,978282.0,-237534.0,-980183.0,281970.0,100743.0,14437.0,-170376.0,15551076.0,2202.0,-57912821,en-US,US,EQUITY,False,Delayed Quote,244057,0.027199998,0.16484846,0.165 - 0.75,-0.5578,-0.74373335,0.165,0.75,1489449600,1560956340,1592405940,1592841600,-0.484,0.21625714,-0.024057135,-0.111243196,0.27455798,-0.08235797,22765322,4,-10.542234,-0.39710745,15,America/New_York,EDT,-14400000,0.19 - 0.209685,0.21485,0.0,0.0,0,0,finmb_404446,Other OTC,Generex Biotechnology Corporation,USD,233620,USD,False,False,0.1922,1630525703,-0.022649989,0.2,0.209685,0.19,286879,PNK,GENEREX BIOTECHNOLOGY CORP,0,us_market,PREPRE,-0.376,-0.29996568,,,,0.75,0.165,0.2163,0.2746,233.62k,244.06k,118.45M,,105.16M,2.42%,0.00%,211.98k,1.73,2.72%,2.66%,101.16k,,,,,,0.00%,"Mar 13, 2017",,7:5,"Feb 24, 2020","Jul 30, 2020","Apr 29, 2021",0.00%,"-4,952.49%",-43.84%,,692.76k,0.01,-95.90%,2.08M,-33.3M,-37.26M,-0.3760,,1.68M,0.01,10.6M,,0.04,-0.48,-2.35M,7.83M,Value,33025,Healthcare,15,"Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.",Miramar,416 364 2551,FL,1609372800,United States,http://generex.com/index.html,86400,10102 USA Today Way,Biotechnology,Suite 200
t-2,GNBT,-88969627,118446000,1170008,,-10989076,13313223,-10730692,13008172,65102,-14113078,-14113078,,-1019080,,,,0,88435,14201513,23333,3124002,,-10989076,-10730692,9134184,418411365,77918304,-45346101,3502122,45885426,108037,306845,-464643597,24975900,34489342,778094,21421,833566,52442565,9958563,778094,197516,2042963,183928,499839,718624,33464414,9607304.0,-60000.0,2155854.0,2247978.0,2215854.0,818114.0,-1335538.0,278310.0,23632.0,-19057.0,-170376.0,-2917062.0,-2202.0,-50399602,en-US,US,EQUITY,False,Delayed Quote,244057,0.027199998,0.16484846,0.165 - 0.75,-0.5578,-0.74373335,0.165,0.75,1489449600,1560956340,1592405940,1592841600,-0.484,0.21625714,-0.024057135,-0.111243196,0.27455798,-0.08235797,22765322,4,-10.542234,-0.39710745,15,America/New_York,EDT,-14400000,0.19 - 0.209685,0.21485,0.0,0.0,0,0,finmb_404446,Other OTC,Generex Biotechnology Corporation,USD,233620,USD,False,False,0.1922,1630525703,-0.022649989,0.2,0.209685,0.19,286879,PNK,GENEREX BIOTECHNOLOGY CORP,0,us_market,PREPRE,-0.376,-0.29996568,,,,0.75,0.165,0.2163,0.2746,233.62k,244.06k,118.45M,,105.16M,2.42%,0.00%,211.98k,1.73,2.72%,2.66%,101.16k,,,,,,0.00%,"Mar 13, 2017",,7:5,"Feb 24, 2020","Jul 30, 2020","Apr 29, 2021",0.00%,"-4,952.49%",-43.84%,,692.76k,0.01,-95.90%,2.08M,-33.3M,-37.26M,-0.3760,,1.68M,0.01,10.6M,,0.04,-0.48,-2.35M,7.83M,Value,33025,Healthcare,15,"Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.",Miramar,416 364 2551,FL,1609372800,United States,http://generex.com/index.html,86400,10102 USA Today Way,Biotechnology,Suite 200
t-3,GNBT,-65310847,118446000,835764,,-11878699,13571607,-11673120,4839426,419344,-5255846,-5255846,,-1651504,,,,0,583632,5839478,164288,-6622853,,-11878699,-11673120,9365526,429744379,53267316,-21455979,1502122,45382944,82251,332268,-452062905,11396206,34489342,780296,21421,15452,41371454,10666703,780296,251808,1254847,164871,499656,742256,23907718,3441685.0,244970.0,244970.0,419145.0,2215854.0,-401191.0,-634224.0,322822.0,168728.0,-22871.0,-170376.0,6089616.0,-11937.0,-40116607,en-US,US,EQUITY,False,Delayed Quote,244057,0.027199998,0.16484846,0.165 - 0.75,-0.5578,-0.74373335,0.165,0.75,1489449600,1560956340,1592405940,1592841600,-0.484,0.21625714,-0.024057135,-0.111243196,0.27455798,-0.08235797,22765322,4,-10.542234,-0.39710745,15,America/New_York,EDT,-14400000,0.19 - 0.209685,0.21485,0.0,0.0,0,0,finmb_404446,Other OTC,Generex Biotechnology Corporation,USD,233620,USD,False,False,0.1922,1630525703,-0.022649989,0.2,0.209685,0.19,286879,PNK,GENEREX BIOTECHNOLOGY CORP,0,us_market,PREPRE,-0.376,-0.29996568,,,,0.75,0.165,0.2163,0.2746,233.62k,244.06k,118.45M,,105.16M,2.42%,0.00%,211.98k,1.73,2.72%,2.66%,101.16k,,,,,,0.00%,"Mar 13, 2017",,7:5,"Feb 24, 2020","Jul 30, 2020","Apr 29, 2021",0.00%,"-4,952.49%",-43.84%,,692.76k,0.01,-95.90%,2.08M,-33.3M,-37.26M,-0.3760,,1.68M,0.01,10.6M,,0.04,-0.48,-2.35M,7.83M,Value,33025,Healthcare,15,"Generex Biotechnology Corporation, through its subsidiaries, engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an oral insulin product. The company is also developing AE37, a synthetic peptide vaccine, which has completed Phase IIb clinical trial to stimulate a potent and specific immune response against tumors expressing the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and test kits and cassettes for testing infectious diseases, as well as Excellagen, a wound conforming gel. Further, the company is developing immunotherapeutic products and vaccines; and extracellular matrix hydrogel solution, a tissue engineered therapy for the treatment of Ulcerative Colitis. Additionally, it manufactures and sells foot and ankle surgical kits that include plates, screws, and tools; and distributes surgical supplies, orthopedic implants, artificial joints, and biologics, medical devices, and regenerative medicine products. It also serves as the general partner of the Management Services Organization. Generex Biotechnology Corporation was founded in 1983 and is headquartered in Miramar, Florida.",Miramar,416 364 2551,FL,1609372800,United States,http://generex.com/index.html,86400,10102 USA Today Way,Biotechnology,Suite 200
